GTHX
Income statement / Annual
Last year (2023), G1 Therapeutics, Inc.'s total revenue was $82.51 M,
an increase of 60.84% from the previous year.
In 2023, G1 Therapeutics, Inc.'s net income was -$47.97 M.
See G1 Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$82.51 M
|
$51.30 M
|
$31.48 M
|
$45.29 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$522,000.00
|
$1.04 M
|
| Cost of Revenue |
$7.20 M |
$3.75 M |
$2.02 M |
$0.00 |
$356,000.00 |
$175,000.00 |
$89,000.00 |
$67,226.00 |
$12.73 M |
$5.02 M |
| Gross Profit |
$75.32 M |
$47.55 M |
$29.46 M |
$45.29 M |
-$356,000.00 |
-$175,000.00 |
-$89,000.00 |
-$67,226.00 |
-$12.21 M |
-$3.98 M |
| Gross Profit Ratio |
0.91 |
0.93 |
0.94 |
1 |
0 |
0 |
0 |
0 |
-23.39 |
-3.81 |
| Research and Development
Expenses |
$43.71 M
|
$83.32 M
|
$76.23 M
|
$73.27 M
|
$89.00 M
|
$70.68 M
|
$53.88 M
|
$25.16 M
|
$12.73 M
|
$5.02 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$68.49 M
|
$40.04 M
|
$18.60 M
|
$7.09 M
|
$5.23 M
|
$3.22 M
|
$2.70 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$71.13 M
|
$100.42 M
|
$95.69 M
|
$68.49 M
|
$40.04 M
|
$18.60 M
|
$7.09 M
|
$5.23 M
|
$3.22 M
|
$2.70 M
|
| Other Expenses |
$2.24 M |
$3,000.00 |
-$346,000.00 |
-$542,000.00 |
$6.59 M |
$4.00 M |
$888,000.00 |
$182,372.00 |
$18,000.00 |
$0.00 |
| Operating Expenses |
$114.84 M |
$183.73 M |
$171.92 M |
$141.76 M |
$129.04 M |
$89.29 M |
$60.97 M |
$30.39 M |
$15.95 M |
$2.70 M |
| Cost And Expenses |
$122.04 M |
$187.48 M |
$173.93 M |
$141.76 M |
$129.04 M |
$89.29 M |
$60.97 M |
$30.39 M |
$15.95 M |
$7.72 M |
| Interest Income |
$2.47 M |
$748,000.00 |
$43,000.00 |
$952,000.00 |
$6.59 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$912.00 |
| Interest Expense |
$10.04 M |
$10.43 M |
$4.67 M |
$1.78 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$513,000.00
|
$530,000.00
|
$469,000.00
|
$582,000.00
|
$356,000.00
|
$175,000.00
|
$89,000.00
|
$67,226.00
|
$42,000.00
|
$17,314.00
|
| EBITDA |
-$39.01 M
|
-$134.90 M
|
-$142.46 M
|
-$95.48 M
|
$0.00
|
$0.00
|
$0.00
|
-$30.32 M
|
-$15.38 M
|
-$6.66 M
|
| EBITDA Ratio |
-0.47 |
-2.63 |
-4.54 |
-2.12 |
0 |
0 |
0 |
0 |
-20.16 |
-6.39 |
| Operating Income Ratio
|
-0.48
|
-2.65
|
-4.53
|
-2.13
|
0
|
0
|
0
|
0
|
-29.55
|
-6.4
|
| Total Other
Income/Expenses Net |
-$5.33 M
|
-$9.68 M
|
-$4.97 M
|
-$1.37 M
|
$6.59 M
|
$4.00 M
|
$847,000.00
|
$100,141.00
|
-$4.84 M
|
-$64.00
|
| Income Before Tax |
-$44.85 M |
-$145.86 M |
-$147.43 M |
-$97.84 M |
-$122.45 M |
-$85.29 M |
-$60.12 M |
-$30.29 M |
-$20.26 M |
-$6.68 M |
| Income Before Tax Ratio
|
-0.54
|
-2.84
|
-4.68
|
-2.16
|
0
|
0
|
0
|
0
|
-38.82
|
-6.4
|
| Income Tax Expense |
$3.12 M |
$1.70 M |
$925,000.00 |
$1.41 M |
-$356,000.00 |
$4.00 M |
$41,000.00 |
$82,231.00 |
$4.86 M |
$502,364.00 |
| Net Income |
-$47.97 M |
-$147.56 M |
-$148.35 M |
-$99.25 M |
-$122.09 M |
-$85.29 M |
-$60.12 M |
-$30.29 M |
-$20.26 M |
-$7.18 M |
| Net Income Ratio |
-0.58 |
-2.88 |
-4.71 |
-2.19 |
0 |
0 |
0 |
0 |
-38.82 |
-6.89 |
| EPS |
-0.93 |
-3.38 |
-3.54 |
-2.62 |
-3.26 |
-2.56 |
-3.3 |
-1.48 |
-0.99 |
-5.85 |
| EPS Diluted |
-0.93 |
-3.38 |
-3.54 |
-2.62 |
-3.26 |
-2.56 |
-3.3 |
-1.48 |
-0.99 |
-5.85 |
| Weighted Average Shares
Out |
$51.73 M
|
$43.63 M
|
$41.94 M
|
$37.88 M
|
$37.50 M
|
$33.32 M
|
$18.20 M
|
$20.43 M
|
$20.43 M
|
$1.23 M
|
| Weighted Average Shares
Out Diluted |
$51.73 M
|
$43.63 M
|
$41.94 M
|
$37.88 M
|
$37.50 M
|
$33.32 M
|
$18.20 M
|
$20.43 M
|
$20.43 M
|
$1.23 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
